研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co.,Ltd.[2]The First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China[3]Cancer Institute and Hospital,Chinese Academy of Medical Sciences Beijing,Beijing,China,100021[4]Beijing Tongren Hospital Beijing,Beijing,China[5]Chongqing Cancer Hospital Chongqing,Chongqing,China,404100[6]Fujian Cancer Hospital Fuzhou,Fujian,China[7]Gansu Province Tumor Hospital Lanzhou,Gansu,China[8]Sun Yat-Sen University Cancer Center Guozhou,Guangdong,China[9]Harbin medical university affiliated tumor hospital Harbin,Heilongjiang,China[10]Henan Province Tumor Hospital Zhengzhou,Henan,China
研究目的：
To compare the effects and safety of Anlotinib with placebo in patients with Medullary Thyroid Carcinoma.
